1,521 research outputs found
Use of direct oral anticoagulants in patients with atrial fibrillation in Scotland : applying a coherent framework to drug utilisation studies
Purpose: To report the use of direct oral anticoagulants (DOAC) for stroke prevention in patients with atrial fibrillation (AF) in Scotland and advocate the standardisation of drug utilisation research methods. Methods: Retrospective cohort study using linked administrative data. Patients included those with a diagnosis of AF (confirmed in hospital) who received a first prescription for a DOAC (dabigatran, rivaroxaban, apixaban) from September 2011 to June 2014. Drug utilisation measures included discontinuation, persistence, and adherence. Results: 5398 patients (mean CHA2DS2-VASc score 2.98 [SD 1.71], 89.7% with ≥ 6 concomitant medicines) were treated with DOACs for a median of 228 days (IQR 105 – 425). Of 35.6% who discontinued DOAC treatment, 11.0% switched to warfarin and 48.3% re-initiated DOACs. Persistence after 12 and 18 months were 75.9% and 69.8%, respectively. Differences between individual DOACs were observed: discontinuation rates ranged from 20.4% (apixaban) to 60.6% (dabigatran), and 12 months persistence from 60.1% (dabigatran) to 85.5% (apixaban). Adherence to treatment with all DOACs was good: overall DOAC median medication refill adherence (MRA) was 102.9% (IQR 88.9% – 115.5%), and 82.3% of patients had an MRA > 80%. Conclusions: In Scotland, adherence to DOAC treatment was good and switching from DOAC to warfarin was low. However, discontinuation and persistence rates were variable – although treatment interruptions were often temporary. To decrease the inconsistencies in drug utilisation methods and facilitate meaningful study comparison, the use of a coherent framework – using a combination of discontinuation, persistence and adherence – and the standardisation of measurements is advocated
Data resource profile : the Scottish national prescribing information system (PIS)
Data Resource Basics: The Prescribing Information System (PIS) covers the prescribed,dispensed and reimbursed prescriptions in community pharmacies from the 5.3 million residents in Scotland. Summary information is available from 1993 and at an individual level from 2009 to the present. Data Collected: The raw data are generated by three data sources: ePrescribed -generated by GPs messages, eDispensed –generated by messages from community pharmacies and Reimbursed messages from scanned paper prescriptions dispensed in the community pharmacies. The four main categories of data collected are: (1) Patient-specific, (2) Prescriber, (3) Dispenser and (4) Drug-specific. PIS data can be linked via a unique identifier to other national databases, including hospital records, maternal and neonatal, the Scottish Cancer Registry and mortality records. The catalogue of databases is available in www.ndc.scot.nhs.uk . Subject to approval of the data controllers other external datasets can also be linked. Data Resource Use: PIS has been used to describe the utilisation of several groups of drugs;factors influencing prescribing and evaluation of interventions to improve it; generation of polypharmacy guidelines; risk of side effects; monitoring of antibiotic use and generation of policy recommendations; associations between community prescription of antimicrobials and deprivation or infection; evaluation of prescription fee abolition; clinical effectiveness, safety and health technology assessment of drugs approved in the last decade. Reasons to be cautious: PIS does not capture information about diagnosis or indication for treatment, over the counter medicines, medicines administered during inpatient hospital stays, upon discharge for short term use, outpatient supplies or some specialist drugs for chronic use. Drug data is currently coded according to the British National Formulary. For longitudinal studies, patient level data is available from 2009 and the frequency of data collection from the three sources is different. Collaboration and data access: PIS data are available upon request to the electronic Data Research and Innovation Service ([email protected]) and project approval by the Public Benefit and Privacy Panel. Funding and competing interests: This dataset is funded from the public monies available to the NHS. Current work to develop an improved PIS research ready analysis platform and this study is supported by the Farr Institute @ Scotland and its 10-funder consortium. The authors declare no conflict of interest
Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland
To compare the clinical effectiveness and safety of direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) in routine clinical practice. Retrospective cohort study using linked administrative data. The study population (n=14,577) included patients with a diagnosis of AF (confirmed in hospital) who initiated DOAC treatment in Scotland between August 2011 and December 2015. Multivariate Cox proportional hazard models were used to estimate hazard ratios of thromboembolic events, mortality, and bleeding events. No differences between the DOACs were observed in the risks of stroke, systemic embolism, or cardiovascular death. In contrast, the risk of myocardial infarction was higher among apixaban patients in comparison to rivaroxaban (1.67 [1.02 - 2.71]), and all-cause mortality was higher among rivaroxaban patients in contrast to both apixaban (1.22 [1.01 - 1.47]) and dabigatran (1.55 [1.16 - 2.05]); rivaroxaban patients also had a higher risk of pulmonary embolism than apixaban patients (5.27 [1.79 - 15.53]). The risk of other major bleeds was higher among rivaroxaban patients compared to apixaban (1.50 [1.10 - 2.03]) and dabigatran (1.58 [1.01 - 2.48]); the risks of gastro-intestinal bleeds and overall bleeding were higher among rivaroxaban patients than among apixaban patients (1.48 [1.01 - 2.16] and 1.52[1.21 - 1.92], respectively). All DOACs were similarly effective in preventing strokes and systemic embolisms, while patients being treated with rivaroxaban exhibited the highest bleeding risks. Observed differences in the risks of all-cause mortality, myocardial infarction, and pulmonary embolism warrant further research. [Abstract copyright: This article is protected by copyright. All rights reserved.
Regulation of Corticosteroidogenic Genes by MicroRNAs
The loss of normal regulation of corticosteroid secretion is important in the development of cardiovascular disease. We previously showed that microRNAs regulate the terminal stages of corticosteroid biosynthesis. Here, we assess microRNA regulation across the whole corticosteroid pathway. Knockdown of microRNA using Dicer1 siRNA in H295R adrenocortical cells increased levels of CYP11A1, CYP21A1, and CYP17A1 mRNA and the secretion of cortisol, corticosterone, 11-deoxycorticosterone, 18-hydroxycorticosterone, and aldosterone. Bioinformatic analysis of genes involved in corticosteroid biosynthesis or metabolism identified many putative microRNA-binding sites, and some were selected for further study. Manipulation of individual microRNA levels demonstrated a direct effect of miR-125a-5p and miR-125b-5p on CYP11B2 and of miR-320a-3p levels on CYP11A1 and CYP17A1 mRNA. Finally, comparison of microRNA expression profiles from human aldosterone-producing adenoma and normal adrenal tissue showed levels of various microRNAs, including miR-125a-5p to be significantly different. This study demonstrates that corticosteroidogenesis is regulated at multiple points by several microRNAs and that certain of these microRNAs are differentially expressed in tumorous adrenal tissue, which may contribute to dysregulation of corticosteroid secretion. These findings provide new insights into the regulation of corticosteroid production and have implications for understanding the pathology of disease states where abnormal hormone secretion is a feature
Use of text-mining methods to improve efficiency in the calculation of drug exposure to support pharmacoepidemiology studies
Background: Efficient generation of structured dose instructions that enable researchers to calculate drug exposure is central to pharmacoepidemiology studies. The aim was to design and test an algorithm to codify dose instructions, applied to the NHS Scotland Prescribing Information System (PIS) that records approximately 100 million prescriptions per annum. Methods: a natural language processing (NLP) algorithm was developed enabling free-text dose instructions to be represented by three attributes: quantity; frequency; and qualifier, each specified by a set of variables. This was tested on a sample of 15 593 distinct dose instructions and manually validated. The final algorithm was then applied to the full dataset. Results: the dataset comprised 458 227 687 prescriptions, of which 99.67% had dose instructions represented by 4 964 083 distinct free-text dose instructions; 13 593 (0.27%) of these occurred ≥1000 times accounting for 88.85% of all prescriptions. Reviewers identified 767 (5.83%) instances where the structured output (n=13 152) was incorrect, an accuracy of 94.2%. Application of the final NLP algorithm to the dataset generated an overall structured output of 92.3% which varied by therapeutic area (86.7% central nervous system to 96.8% cardiovascular). Conclusion: We adopted a zero assumption approach to create an NLP algorithm, operational at scale, to produce structured output which enables data users maximum flexibility to formulate, test and apply their own assumptions according to the medicines under investigation. Text mining approaches can provide a solution to the safe and efficient management and provisioning of large volumes of data generated through our health systems
Use of record linkage to evaluate treatment outcomes and trial eligibility in a 1 real-world metastatic prostate cancer population in Scotland
Purpose: New treatments are introduced into standard care based on clinical trial results. However, it is not clear if these benefits are reflected in the broader population. This study analysed the clinical outcomes of patients with metastatic castration-resistant prostate cancer, treated with abiraterone and enzalutamide, within the Scottish National Health Service. Methods: Retrospective cohort study using record linkage of routinely collected healthcare data (study period: February 2012 to February 2017). Overall survival (OS) was analysed using Kaplan-Meier methods and Cox Proportional Hazard models; a subgroup analysis comprised potentially trial-eligible patients. Results: Overall, 271 patients were included and 73.8% died during the study period. Median OS was poorer than in the pivotal trials, regardless of medication and indication: 10.8 months (95% confidence interval [CI] 8.6-15.1) and 20.9 months (95% CI 14.9-29.0) for abiraterone, and 12.6 months (95% CI 10.5-18.2) and 16.0 months (95% CI 9.8—not reached) for enzalutamide, post and pre chemotherapy, respectively. Only 46% of patients were potentially “trial eligible” and in this subgroup OS improved. Factors influencing survival included baseline performance status, and baseline prostate-specific antigen, alkaline phosphatase, and albumin levels. Conclusions: Poorer prognostic features of non-trial eligible patients impact real-world outcomes of cancer medicines. Electronic record linkage of routinely collected healthcare data offers an opportunity to report outcomes on cancer medicines at scale and describe population demographics. The availability of such observational data to supplement clinical trial results enables patients and clinicians to make more informed treatment decisions, and policymakers to contextualise trial findings
Response to lower dose TNF inhibitors in axial spondyloarthritis; a real-world multicentre observational study
Objective: Dose optimization of TNF inhibitors in axial spondyloarthritis (axSpA) is attractive, but it is unclear for which patients this approach might be appropriate. Methods: Seventy-one patients with axSpA, from six UK centres, were identified who had reduced their dose of TNF inhibitor after being considered to be stable responders. All completed a questionnaire concerning their approach to and experience of dose reduction. Data on patient characteristics, metrology and CRP were retrieved retrospectively from patient records. Results: Over 2 years of observation, 60 (84.5%) remained (REM) on reduced-dose medication and 11 (15.5%) reverted (REV) to the original dose. The overall mean dose reduction was 39% for REM patients and 44% for REV patients. Both groups initially responded in a similar manner to treatment, but the data showed a trend that younger women were more likely to revert. Neither BMI nor smoking was associated with continued low-dose responsiveness. Eight of the 11 REV patients reverted by 6 months. None reached criteria of secondary drug failure, and all regained control after increasing back to the original dose. Most patients in both groups reached the decision to reduce the dose jointly with clinicians. A preference for taking the reduced dose was not associated with low-dose drug survival. Conclusion: Many patients with axSpA remain well symptomatically after stepping down the dose of TNF inhibitor, but young women are less likely to do well on a reduced dose. Dose reduction should be one element of the management of patients with axSpA
Common Polymorphisms at the <i>CYP17A1 </i>Locus Associate With Steroid Phenotype:Support for Blood Pressure Genome-Wide Association Study Signals at This Locus
Genome-wide association studies implicate the CYP17A1 gene in human blood pressure regulation although the causative polymorphisms are as yet unknown. We sought to identify common polymorphisms likely to explain this association. We sequenced the CYP17A1 locus in 60 normotensive individuals and observed 24 previously identified single-nucleotide polymorphisms with minor allele frequency >0.05. From these, we selected, for further studies, 7 polymorphisms located ≤2 kb upstream of the CYP17A1 transcription start site. In vitro reporter gene assays identified 3 of these (rs138009835, rs2150927, and rs2486758) as having significant functional effects. We then analyzed the association between the 7 polymorphisms and the urinary steroid metabolites in a hypertensive cohort (n=232). Significant associations included that of rs138009835 with aldosterone metabolite excretion; rs2150927 associated with the ratio of tetrahydrodeoxycorticosterone to tetrahydrodeoxycortisol, which we used as an index of 17α-hydroxylation. Linkage analysis showed rs138009835 to be the only 1 of the 7 polymorphisms in strong linkage disequilibrium with the blood pressure–associated polymorphisms identified in the previous studies. In conclusion, we have identified, characterized, and investigated common polymorphisms at the CYP17A1 locus that have functional effects on gene transcription in vitro and associate with corticosteroid phenotype in vivo. Of these, rs138009835—which we associate with changes in aldosterone level—is in strong linkage disequilibrium with polymorphisms linked by genome-wide association studies to blood pressure regulation. This finding clearly has implications for the development of high blood pressure in a large proportion of the population and justifies further investigation of rs138009835 and its effects
Discontinuation, persistence and adherence to subcutaneous biologics delivered via a homecare route to Scottish adults with rheumatic diseases: a retrospective study
ObjectivesTo understand patterns of subcutaneous (SC) biologics use over time in adults with inflammatory rheumatic musculoskeletal diseases receiving a homecare delivery service.DesignRetrospective cohort.SettingPatients in secondary care receiving SC biologics in the largest Scottish Health Board.ParticipantsA new bespoke cohort was created from routine data gathered as part of a health board Homecare Service Database. Patients over 18 years who received a supply of SC biologic from January 2012 to May 2015 with a diagnosis for rheumatoid arthritis (RA), psoriatic arthritis (PsA) or ankylosing spondylitis (AS) were included.Outcomes measuredA standardised framework was applied by measuring discontinuation rates, persistence using Kaplan-Meier analysis and Cox regression and adherence using medication refill adherence (MRA) and compliance rate (CR).Results751 patients were identified (AS: 105, PsA: 227, RA: 419) of whom 89.3% had more than one biologic delivery (median days’ follow-up: AS: 494; PsA: 544; RA: 529) and 83.2% did not switch biologic. For all conditions, approximately half were persistent on their index biologic (52% AS, 54% PsA, 48%RA). Of patients who discontinued treatment, the majority reinitiated with the same biologic (19% AS, 18% PsA and 21% RA). Overall adherence during the period of treatment was over 80% when calculated using MRA (median %MRA: AS: 84.0%, PsA: 85.0%, RA: 82.4%) or CR (median %CR: AS: 96.6%, PsA: 97%, RA: 96.6%).ConclusionUse of linked routine data is a sustainable pathway to enable ongoing evaluation of biologics use. A more consistent approach to studying use (discontinuation, persistence and adherence metrics) should be adopted to enable comparability of studies.</jats:sec
Economic and epidemiological impact of dengue illness over 16 years from a public health system perspective in Brazil to inform future health policies including the adoption of a dengue vaccine
Introduction: Dengue is a serious global health problem endemic in Brazil. Consequently, our aim was to measure the costs and disease burden of symptomatic dengue infections in Brazil from the perspective of the Brazilian Public Health System (SUS) between 2000 and 2015 using Brazilian public health system databases. Specific age group incidence estimates were used to calculate the disability-adjusted life years (DALYs) to gain a better understanding of the disease burden. Areas covered: SUS spent almost USD159 million and USD10 million to treat dengue and severe dengue, respectively, between 2000-2015. This is principally hospitalization costs with the majority of patients self-treated at home with minor symptoms. The average notification rate for dengue was 273 per 100,000 inhabitants and 3 per 100,000 for severe dengue, with annual DALYs estimates ranging between 72.35 to 6,824.45 during the 16 years. Expert commentary: The epidemiological and morbidity burden associated with dengue is substantial in Brazil, with costs affected by the fact that most patients self-treat at home with these costs not included in SUS. The Brazilian government urgently needs to proactively evaluate the real costs and clinical benefits of any potential dengue vaccination program by the National Immunization Program to guide future decision making
- …